- Home
- PMVP vs CRDL Comparison
PMVP vs CRDL Comparison
Compare PMVP & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- CRDL
- Stock Information
- Founded
- PMVP 2013
- CRDL 2017
- Country
- PMVP United States
- CRDL Canada
- Employees
- PMVP N/A
- CRDL N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMVP Health Care
- CRDL Health Care
- Exchange
- PMVP Nasdaq
- CRDL Nasdaq
- Market Cap
- PMVP 71.9M
- CRDL 80.1M
- IPO Year
- PMVP 2020
- CRDL N/A
- Fundamental
- Price
- PMVP $0.88
- CRDL $1.24
- Analyst Decision
- PMVP Strong Buy
- CRDL Strong Buy
- Analyst Count
- PMVP 1
- CRDL 3
- Target Price
- PMVP $5.00
- CRDL $9.33
- AVG Volume (30 Days)
- PMVP 313.5K
- CRDL 150.7K
- Earning Date
- PMVP 05-09-2025
- CRDL 05-14-2025
- Dividend Yield
- PMVP N/A
- CRDL N/A
- EPS Growth
- PMVP N/A
- CRDL N/A
- EPS
- PMVP N/A
- CRDL N/A
- Revenue
- PMVP N/A
- CRDL N/A
- Revenue This Year
- PMVP N/A
- CRDL N/A
- Revenue Next Year
- PMVP N/A
- CRDL N/A
- P/E Ratio
- PMVP N/A
- CRDL N/A
- Revenue Growth
- PMVP N/A
- CRDL N/A
- 52 Week Low
- PMVP $0.81
- CRDL $0.77
- 52 Week High
- PMVP $1.85
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- PMVP 39.59
- CRDL 61.96
- Support Level
- PMVP $0.87
- CRDL $1.04
- Resistance Level
- PMVP $0.94
- CRDL $1.31
- Average True Range (ATR)
- PMVP 0.06
- CRDL 0.08
- MACD
- PMVP 0.01
- CRDL 0.01
- Stochastic Oscillator
- PMVP 50.38
- CRDL 74.26
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.